KBY Biotech Indexv0.0.34
Search
← Pipeline|Tirazasiran

Tirazasiran

Phase 1/2
CLE-1317
By Clementia (Ipsen)
Source: Trial-derived·Trials: 2
Modality
Peptide
MOA
RAS(ON)i
Target
BET
Pathway
mTOR
WilmsMCL
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
Feb 2017
→ Apr 2031
Phase 1Current
NCT06585386
2,625 pts·Wilms
2017-02→2030-06·Completed
NCT03753915
1,383 pts·MCL
2023-12→2031-04·Terminated
4,008 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-06-124.2y awayPh2 Data· Wilms
2031-04-275.1y awayPh2 Data· MCL
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Complet…
P1/2
Termina…
Catalysts
Ph2 Data
2030-06-12 · 4.2y away
Wilms
Ph2 Data
2031-04-27 · 5.1y away
MCL
CompletedTerminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT06585386Phase 1/2WilmsCompleted2625HbA1c
NCT03753915Phase 1/2MCLTerminated1383UPCR
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-5767PfizerPhase 1/2BETCDK4/6i
RHH-1969RocheApprovedBETCDK4/6i
NVS-5439NovartisPreclinicalBETAnti-Tau
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
IvocapivasertibBristol-Myers SquibbPhase 1BETCDK4/6i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
AdagracapivasertibBeiGeneNDA/BLABETCDK4/6i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i